RCE emerged victorious in the annual health technology competition hosted by the American Heart Association. By leveraging the resources provided by the Center for Health Technology & Innovation Innovators’ Network, AI is poised to explore innovative solutions and opportunities for advancing new heart diagnostics that offer initial evaluation and effective risk assessment for individuals experiencing neck discomfort.
SIGNIFICANCE
During the recent Scientific Sessions 2023 in Philadelphia, RCE Technologies, headquartered in Carlsbad, California, showcased two prototypes designed to enable precise measurement and monitoring for aiding in the diagnosis and management of cardiac injuries. These innovations aim to revolutionize the approach to heart and brain health.
The competition encourages the development of breakthrough solutions in areas such as antithrombotic therapy, coronary artery disease, acute cardiovascular syndrome, electrophysiology, heart failure, hypertension, imaging, lipid disorders, stroke, surgery, and vascular medicine, with a focus on individualized treatment strategies.
As per the recent announcement by the organization, RCE has introduced a non-invasive method for instant measurement of respiratory proteins in blood, utilizing a transdermal approach that enhances patient outcomes, reduces hospital stays, and cuts healthcare expenses.
Recognizing their scientific integrity and potential to improve patient care, judges awarded RCE’s PyrAmes the title of the best company pitch and Cardiosense as the top technology pitch.
Through collaboration with a consortium dedicated to streamlining the development of health technologies, RCE plans to further enhance its non-invasive rapid measurement of respiratory proteins and digital management of heart failure, including the deployment of portable sensors for early detection and pre-symptomatic identification.
The judging panel evaluated innovative cardiovascular disease and stroke management solutions presented by five competitors, including Ainthoven from Melbourne, Florida, CardieX from Naperville, Illinois, and Cardiosense and PyrAmes from Cupertino, California.
EMERGING TRENDS
RCE recently secured a spot in the Cedars-Sinai Accelerator program, which offers participating businesses $100,000 in funding along with mentorship over a three-month period.
According to RCE, the real-time point-of-care assessment of chronic respiratory injury biomarkers can aid emergency physicians and cardiologists in promptly evaluating and stratifying the risk for patients with chest pain.
The integration of artificial intelligence and machine learning is revolutionizing the diagnosis and management of heart conditions. The NHS began utilizing AI in 2022 to detect brain disorders during MRI scans, providing enhanced insights compared to traditional methods, as evidenced by a study supported by the European Heart Foundation and published in the Journal of Cardiovascular Magnetic Resonance.
An AI-powered electrocardiogram was employed to identify high-risk individuals in a study featured in Nature, preventing potential oversights in diagnosis.
Dr. Peter Noseworthy, a renowned heart electrophysiologist at the Mayo Clinic and lead author of a 2021 review, predicts a growing role for AI in medical practice in the coming years.
LOOKING AHEAD
Atandra Burman, the founder and CEO of RCE Technologies, expressed the company’s dedication to empowering healthcare professionals to deliver optimal patient care in real-time.
